acetylcarnitine has been researched along with Recrudescence in 2 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 9.19 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 6.79 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 5.19 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 2.79 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Callander, N | 1 |
| Markovina, S | 1 |
| Eickhoff, J | 1 |
| Hutson, P | 1 |
| Campbell, T | 1 |
| Hematti, P | 1 |
| Go, R | 1 |
| Hegeman, R | 1 |
| Longo, W | 1 |
| Williams, E | 1 |
| Asimakopoulos, F | 1 |
| Miyamoto, S | 1 |
| Goodison, G | 1 |
| Overeem, K | 1 |
| de Monte, V | 1 |
| Siskind, D | 1 |
1 trial available for acetylcarnitine and Recrudescence
| Article | Year |
|---|---|
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug | 2014 |
1 other study available for acetylcarnitine and Recrudescence
| Article | Year |
|---|---|
Mania associated with self-prescribed acetyl-l-carnitine in a man with bipolar I disorder.
Topics: Acetylcarnitine; Adult; Bipolar Disorder; Dietary Supplements; Humans; Male; Psychoses, Substance-In | 2017 |